Clinical effects of human macrophage inflammatory protein-1 alpha MIP-1 alpha (LD78) administration to humans: a phase I study in cancer patients and normal healthy volunteers with the genetically engineered variant, BB-10010.
Hunter, M G
Wood, L M
Testa, Nydia G
Dexter, T Michael
Lord, Brian I
AffiliationCRC Department of Medical Oncology, Christie Hospital, Manchester, U.K.
MetadataShow full item record
AbstractBB-10010 is a genetically engineered variant of human macrophage inflammatory protein-1 alpha (hMIP-1 alpha) with improved pharmaceutical formulation properties. Although initially described as a pro-inflammatory cytokine, it is now recognised that hMIP-1 alpha has additional effects on haemopoietic stem cell cycling and on human immunodeficiency virus uptake by macrophages. In view of the potential clinical utility of the molecule, we have embarked on a clinical trials programme to evaluate the safety, tolerability and haematological effects of BB-10010. We now report the results of two phase I clinical studies in which 49 subjects (9 patients with advanced breast carcinoma and 40 normal healthy volunteers) received escalating doses of BB-10010, from 0.1 to 300 micrograms/kg using the subcutaneous (s.c.) or intravenous route (i.v.) of administration. Treatment was associated with a dose-related increase in monocyte count which peaked at 200% of steady-state levels and was preceded by an acute, short-lived, monocytopenia, 50-100% of baseline. no measurable effects were noted on other leucocyte subsets or on circulating progenitor cell numbers. In all cases, BB-10010 was extremely well tolerated with no significant toxicity observed at any dose level and a maximum tolerated dose was not defined. Pharmacokinetic analysis revealed that serum concentrations of BB-10010 were detectable using doses of > or = 10 micrograms/kg i.v. or > or = 30 micrograms/kg s.c., and that a single s.c. injection resulted in sustained plasma levels over a 24 h period. These preliminary studies have confirmed the safety and tolerability of BB-10010 using a dose range up to 300 micrograms/kg. Further clinical studies are ongoing to determine the biological effects and to investigate the potential myeloprotective properties using a variable dose range and schedule of BB-10010 in combination with cytotoxic chemotherapy.
CitationClinical effects of human macrophage inflammatory protein-1 alpha MIP-1 alpha (LD78) administration to humans: a phase I study in cancer patients and normal healthy volunteers with the genetically engineered variant, BB-10010. 1998, 34 (7):1023-9 Eur. J. Cancer
JournalEuropean Journal of Cancer
- A randomized phase-II study of BB-10010 (macrophage inflammatory protein- 1alpha) in patients with advanced breast cancer receiving 5-fluorouracil, adriamycin, and cyclophosphamide chemotherapy.
- Authors: Clemons MJ, Marshall E, Dürig J, Watanabe K, Howell A, Miles D, Earl H, Kiernan J, Griffiths A, Towlson K, DeTakats P, Testa NG, Dougal M, Hunter MG, Wood LM, Czaplewski LG, Millar A, Dexter TM, Lord BI
- Issue date: 1998 Sep 1
- A randomized phase II study of BB-10010: a variant of human macrophage inflammatory protein-1alpha for patients receiving high-dose etoposide and cyclophosphamide for malignant lymphoma and breast cancer.
- Authors: Bernstein SH, Eaves CJ, Herzig R, Fay J, Lynch J, Phillips GL, Christiansen N, Reece D, Ericson S, Stephan M, Kovalsky M, Hawkins K, Rasmussen H, Devos A, Herzig GP
- Issue date: 1997 Dec
- BB-10010: an active variant of human macrophage inflammatory protein-1 alpha with improved pharmaceutical properties.
- Authors: Hunter MG, Bawden L, Brotherton D, Craig S, Cribbes S, Czaplewski LG, Dexter TM, Drummond AH, Gearing AH, Heyworth CM, Lord BI, McCourt M, Varley PG, Wood LM, Edwards RM, Lewis PJ
- Issue date: 1995 Dec 15
- Continuous infusion of macrophage inflammatory protein MIP-1alpha enhances leucocyte recovery and haemopoietic progenitor cell mobilization after cyclophosphamide.
- Authors: Marshall E, Woolford LB, Lord BI
- Issue date: 1997
- BB-10010/MIP-1 alpha in vivo maintains haemopoietic recovery following repeated cycles of sublethal irradiation.
- Authors: Lord BI, Marshall E, Woolford LB, Hunter MG
- Issue date: 1996 Oct